{"id":"long-acting-octreotide","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Abdominal pain"},{"rate":"15-25","effect":"Nausea"},{"rate":"15-20","effect":"Cholelithiasis"},{"rate":"10-15","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells and tumor cells. This binding suppresses the release of growth hormone, insulin, glucagon, and other hormones, as well as inhibiting angiogenesis and tumor cell proliferation. The long-acting formulation provides sustained therapeutic levels over weeks to months.","oneSentence":"Long-acting octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:23.187Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Neuroendocrine tumors (carcinoid syndrome, VIPomas)"},{"name":"Gastroenteropancreatic neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT06784752","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-05-30","conditions":"Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)","enrollment":240},{"nctId":"NCT03972488","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2020-01-08","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":226},{"nctId":"NCT05364944","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2022-05-18","conditions":"Acromegaly, GEP-NET","enrollment":19},{"nctId":"NCT07165886","phase":"PHASE2, PHASE3","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-08-29","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":243},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT06345079","phase":"PHASE2","title":"Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2024-10-14","conditions":"Neuroendocrine Tumors","enrollment":78},{"nctId":"NCT07057622","phase":"PHASE3","title":"A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs","status":"RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2023-12-12","conditions":"NETS Ga68 Lu177","enrollment":184},{"nctId":"NCT03289741","phase":"PHASE4","title":"A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-19","conditions":"Neuroendocrine Tumors","enrollment":51},{"nctId":"NCT00113360","phase":"PHASE2","title":"RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-01","conditions":"Neuroendocrine Carcinoma, Islet Cell Carcinoma","enrollment":67},{"nctId":"NCT00463983","phase":"PHASE1, PHASE2","title":"Treatment of Idiopathic Pulmonary Fibrosis with Long Acting Octreotide","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-10","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":25},{"nctId":"NCT02736448","phase":"PHASE2","title":"177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-05","conditions":"Gastro-entero-pancreatic Neuroendocrine Tumors","enrollment":35},{"nctId":"NCT06505395","phase":"PHASE2","title":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-07-30","conditions":"Gastrointestinal Neuroendocrine Pancreatic Tumor","enrollment":90},{"nctId":"NCT05701241","phase":"PHASE4","title":"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-06-28","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":270},{"nctId":"NCT03377660","phase":"","title":"Resection of the Esophagus and Subsequent Weight Loss","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2018-01-01","conditions":"Esophageal Cancer, Weight Gain, Eating Behavior","enrollment":30},{"nctId":"NCT05761431","phase":"PHASE1","title":"A Single-dose Study of Octreotide Injection in Healthy Adult Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-03-02","conditions":"Acromegaly","enrollment":56},{"nctId":"NCT05884255","phase":"PHASE3","title":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-07-06","conditions":"Advanced Gastroenteropancreatic Neuroendocrine Tumor","enrollment":220},{"nctId":"NCT03967249","phase":"PHASE2","title":"Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2019-07-25","conditions":"Acromegaly","enrollment":39},{"nctId":"NCT04129255","phase":"PHASE2","title":"Octreotide LAR in the Induction of Immunologic Response in NENs Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2017-06-28","conditions":"Neuroendocrine Tumors","enrollment":34},{"nctId":"NCT00092287","phase":"PHASE3","title":"Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome","status":"TERMINATED","sponsor":"Ipsen","startDate":"2004-07","conditions":"Malignant Carcinoid Syndrome","enrollment":4},{"nctId":"NCT00171873","phase":"PHASE3","title":"Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut","status":"COMPLETED","sponsor":"Carmen Schade-Brittinger","startDate":"2001-09","conditions":"Neuroendocrine Tumors","enrollment":85},{"nctId":"NCT03812939","phase":"","title":"Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-01-01","conditions":"Gastric NET","enrollment":30},{"nctId":"NCT00853047","phase":"PHASE2","title":"Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2009-03","conditions":"Carcinoid Syndrome","enrollment":23},{"nctId":"NCT03017690","phase":"","title":"Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"COMPLETED","sponsor":"Ipsen","startDate":"2017-04-12","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":22},{"nctId":"NCT00552071","phase":"PHASE4","title":"Ultrasound Guided Octreotide LAR Injection in Acromegaly","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2007-07","conditions":"Acromegaly","enrollment":15},{"nctId":"NCT02874326","phase":"PHASE2","title":"Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-10","conditions":"Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage, Anemia","enrollment":15},{"nctId":"NCT01137682","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-07-19","conditions":"Acromegaly","enrollment":198},{"nctId":"NCT01377246","phase":"PHASE3","title":"Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2011-05","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":100},{"nctId":"NCT00600886","phase":"PHASE3","title":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-02-11","conditions":"Acromegaly","enrollment":358},{"nctId":"NCT02668172","phase":"PHASE4","title":"Pasireotide LAR and Pegvisomant Study in Acromegaly","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2015-08","conditions":"Acromegaly","enrollment":60},{"nctId":"NCT00033605","phase":"PHASE3","title":"Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-04","conditions":"Cervical Cancer, Colorectal Cancer, Diarrhea","enrollment":130},{"nctId":"NCT00241020","phase":"PHASE3","title":"Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-06","conditions":"Advanced Hepatocellular Carcinoma","enrollment":270},{"nctId":"NCT00432068","phase":"PHASE1","title":"Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Healthy Cholecystectomized","enrollment":48},{"nctId":"NCT01157858","phase":"PHASE2","title":"Everolimus and LongActing Octreotide Trial in Polycystic Livers","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2010-06","conditions":"Polycystic Liver Disease","enrollment":44},{"nctId":"NCT00582426","phase":"PHASE3","title":"Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Chemotherapy-induced Diarrhea","enrollment":139},{"nctId":"NCT02427295","phase":"PHASE4","title":"Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-03","conditions":"Acromegaly","enrollment":1},{"nctId":"NCT01886287","phase":"PHASE2","title":"P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-12","conditions":"Neuroendocrine Carcinoma","enrollment":2},{"nctId":"NCT00690430","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Symptomatic Refractory Resistant Carcinoid Disease","enrollment":186},{"nctId":"NCT00309283","phase":"PHASE3","title":"Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2006-04","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":78},{"nctId":"NCT00426153","phase":"PHASE2, PHASE3","title":"Octreotide in Severe Polycystic Liver Disease","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-01","conditions":"Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly","enrollment":42},{"nctId":"NCT00128232","phase":"PHASE3","title":"Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-12","conditions":"Acromegaly","enrollment":100},{"nctId":"NCT00225979","phase":"PHASE3","title":"Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-11","conditions":"Acromegaly","enrollment":100},{"nctId":"NCT00332696","phase":"PHASE2","title":"Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis","enrollment":64},{"nctId":"NCT01203306","phase":"PHASE2","title":"Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2006-01","conditions":"Neuroendocrine Carcinomas","enrollment":42},{"nctId":"NCT01188733","phase":"PHASE1, PHASE2","title":"Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"1998-06","conditions":"Cirrhosis, Portal Hypertension, Esophageal Varices","enrollment":39},{"nctId":"NCT00953394","phase":"PHASE2","title":"5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2002-02","conditions":"Neuroendocrine Tumors","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":212,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"long-acting Octreotide.","genericName":"long-acting Octreotide.","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Long-acting octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors. Used for Acromegaly, Neuroendocrine tumors (carcinoid syndrome, VIPomas), Gastroenteropancreatic neuroendocrine tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}